Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swapna Verma

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Schizophrenia Bulletin|December 20, 2024
Characterizing the Clinical Trajectory and Predicting Persistence and Deterioration of Attenuated Psychotic Symptoms in Ultra-High-Risk IndividualsCassandra Wannan, Isabelle Scott, Dominic Dwyer, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 16, 2024
Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra-high risk in the UHR 1000+ cohortSimon Hartmann, Dominic Dwyer, Blake Cavve, et al.
Schizophrenia Bulletin|January 20, 2024
Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development StudyJonah F Byrne, Colm Healy, Melanie Föcking, et al.
Social Psychiatry and Psychiatric Epidemiology|January 5, 2021
The association between migrant status and transition in an ultra-high risk for psychosis populationBrian O'Donoghue, Hellen Geros, Holly Sizer, et al.
Schizophrenia Bulletin Open|July 16, 2026
Relationship among Sleep Disturbance, Stress, and Suicidal Ideation in Clinical High Risk for PsychosisHeather M Wastler, Aubrey Moe, Alexandra M Blouin, et al.
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Schizophrenia Bulletin|December 20, 2024
Characterizing the Clinical Trajectory and Predicting Persistence and Deterioration of Attenuated Psychotic Symptoms in Ultra-High-Risk IndividualsCassandra Wannan, Isabelle Scott, Dominic Dwyer, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 16, 2024
Development and temporal validation of a clinical prediction model of transition to psychosis in individuals at ultra-high risk in the UHR 1000+ cohortSimon Hartmann, Dominic Dwyer, Blake Cavve, et al.
Schizophrenia Bulletin|January 20, 2024
Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development StudyJonah F Byrne, Colm Healy, Melanie Föcking, et al.
Social Psychiatry and Psychiatric Epidemiology|January 5, 2021
The association between migrant status and transition in an ultra-high risk for psychosis populationBrian O'Donoghue, Hellen Geros, Holly Sizer, et al.
Schizophrenia Bulletin Open|July 16, 2026
Relationship among Sleep Disturbance, Stress, and Suicidal Ideation in Clinical High Risk for PsychosisHeather M Wastler, Aubrey Moe, Alexandra M Blouin, et al.
Schizophrenia Bulletin Open|August 27, 2025
Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Amy Shalev, Lu Liu, et al.
Schizophrenia (Heidelberg, Germany)|April 3, 2025
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia ProgramJean Addington, Lu Liu, Amy Braun, et al.
Schizophrenia Bulletin|May 11, 2026
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-SchizophreniaHenry R Cowan, Danielle Pratt, Jai L Shah, et al.
Schizophrenia Bulletin Open|August 27, 2025
Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia ProgramJean Addington, Lu Liu, Monica Chu, et al.
Schizophrenia (Heidelberg, Germany)|October 15, 2025
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiativeZarina R Bilgrami, Eduardo Castro, Carla Agurto, et al.
Pageof 16